Accueil > Événements > Séminaires

Séminaire Chimie ED459 / Chaire Total

3 lectures on nanoparticles and nanotherapeutics for cancer treatement

Dr. Nikola Ž. Knežević (Faculty of Pharmacy, European University, Novi Sad, Serbia / Prof. invité Chaire Total Balard)

publié le , mis à jour le

Trois séminaires à l’UM2 :
Jeudi 18 septembre 2014 à 13h45, salle de cours SC-12.01 :
Synthesis, functionalization and characterization of mesoporous silica nanoparticle-based drug carriers for stimuli-responsive anticancer treatment
Jeudi 30 octobre 2014 à 13h45, salle de cours SC-25.01 :
Construction of biocompatible nanoparticles for cancer tissue-targeting
Jeudi 27 novembre 2014 à 13h45, salle de cours SC-25.01 :
Nanotherapeutics for anticancer treatment

1. Synthesis, functionalization and characterization of mesoporous silica nanoparticle-based drug carriers for stimuli-responsive anticancer treatment

Jeudi 18 septembre à 13h45, UM2 salle SC-12.01

Construction of stimuli-responsive drug delivery systems has been an attractive research field in recent years due to possible application for selective anticancer treatment. Mesoporous silica nanoparticles (MSNs) are particularly attractive scaffolds for construction of such drug delivery nanodevices due to high surface area, isostructural mesoporosity and suitable particle diameter. Drugs can be loaded inside the mesoporous framework and entrapped by the addition of various mesopore capping agents. Cargo molecules are then released only upon exposure to stimuli, which induce the removal of capping moieties and facilitate the control over delivery process. This lecture overviews construction and characterization of stimuli-responsive (light, pH, magnetic field) controlled release assemblies for drug delivery and anticancer treatment, based on functionalized MSN and their cores/shell analogues.

2. Construction of biocompatible nanoparticles for cancer tissue-targeting

Jeudi 30 octobre à 13h45 – UM2 salle SC-25.01

Intrinsic properties characteristic for tumor tissues will be discussed which can be utilized for construction of cancer-targeting nanotherapeutics (enhanced permeability and retention effect, overexpressed receptors and acidic extracellular pH). Recent literature reports which showcase succesful cancer targeting by mesoporous silica nanoparticle-based nanotherapeutics, by taking advantage of characteristic tumor environment, in addition to stimuli responsive drug and gene delivery capability will be accounted.

3. Nanotherapeutics for anticancer treatment

Jeudi 27 novembre à 13h45 – UM2 salle SC-25.01

Much of the research focus in recent years was devoted to construction of nanotherapeutics with the ability to selectively localize the activity of anticancer agents to tumor tissues in order to avoid their adverse effects. This seminar will offer an overview of various strategies for anticancer therapy through drug delivery and photodynamic therapy by employing polymeric, liposomal and nanoparticulate carriers.

References

1.1. N. Ž. Knežević, B. G. Trewyn, V. S. Y. Lin, Chemistry – A European Journal, 17, 3338 (2011).
1.2. N. Ž. Knežević, B. G. Trewyn, V. S. Y. Lin, Chemical Communications, 47, 2817 (2011).
1.3. N. Ž. Knežević, I. I. Slowing, V. S. Y. Lin, ChemPlusChem, 77, 48 (2012).
1.4. N. Ž. Knežević, V. S. Lin, Nanoscale, 5, 1544 (2013).
1.5. N. Ž. Knežević, RSC Advances, 3, 19388 (2013).

2.1. J. Li, F. Chen, et al., Targeted oncology, 7, 69 (2012).
2.2. J. Lu, M. Liong, Z. Li, J. I. Zink, F. Tamanoi, Small, 6, 1794 (2010).
2.3. F. Chen, H. Hong, Y. Zhang, H. F. Valdovinos, S. Shi, G. S. Kwon, C. P. Theuer, T. E. Barnhart, W. Cai, ACS Nano, 7, 9027 (2013).
2.4. N. Ž. Knežević, E. Ruiz-Hernandez, W. E. Hennink, M. Vallet-Regi, RSC Advances, 3, 9584 (2013).

3.1. J. Nicolas, S. Mura, D. Brambilla, N. Mackiewicz, P. Couvreur, Chem. Soc. Rev., 42, 1147 (2013).
3.2. T. M. Allen, P. R. Cullis, Adv. Drug Delivery Rev., 65, 36 (2013).
3.3. P. Agostinis, K. Berg, K. A. Cengel, T. H. Foster, A. W. Girotti, S. O. Gollnick, S. M. Hahn, M. R. Hamblin, A. Juzeniene, D. Kessel, M. Korbelik, J. Moan, P. Mroz, D. Nowis, J. Piette, B. C. Wilson, J. Golab, CA : A Cancer Journal for Clinicians, 61, 250 (2011).

Contact local ICGM : Dr. Jean-Olivier Durand (équipe CMOS)

Agenda

Ajouter un événement iCal